144875-48-9
144875-48-9
Chemical Structure
Resiquimod
Synonym(s): R848; S28463
- CAS No.: 144875-48-9
- Formula:C17H22N4O2
- Molecular Weight:314.39
IUPAC Name: 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol
InChIKey: BXNMTOQRYBFHNZ-UHFFFAOYSA-N
SMILES: OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N
Biological Activity: Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Resiquimod | 99.87% | Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Resiquimod (GMP) | Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Resiquimod (Standard) | ≥98% | Resiquimod (Standard) is the analytical standard of Resiquimod. This product is intended for research and analytical applications. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Resiquimod-d5 | 98.33% | Resiquimod-d5 is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gardiquimod | 99.78% | Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gardiquimod hydrochloride | Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TLR7 agonist 3 | 99.90% | TLR7 agonist 3 (compound 2) is a TLR7 agonist and can be used for the stuy of cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3M-011 | 3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TLR7/8 agonist 3 | 99.96% | TLR7/8 agonist 3 (Compound II) is a potent TLR7 and TLR8 agonist, extracted from patent WO2016057618 (compound of formula (II)). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TLR7 agonist 4 | 98.87% | TLR7 agonist 4 is a TLR7 agonist with pro-inflammatory cytokine-stimulating activity. TLR7 agonist 4 modulates TLR7 activity to stimulate the production of pro-inflammatory cytokines. TLR7 agonist 4 stimulates mouse bone marrow-derived macrophages to produce the pro-inflammatory cytokine TNFα. TLR7 agonist 4 can be conjugated with antibodies to form conjugates. TLR7 agonist 4 is applicable to cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AXC-666 | 99.75% | AXC-666, an immune agonist, is a Imiquimod (HY-B0180) derivative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Hydroxy Imiquimod | 2-Hydroxy Imiquimod (R-842), a hydroxylated metabolite of Imiquimod (HY-B0180), is an immunomodulating agent. 2-Hydroxy Imiquimod can induce IFN-α, TNF-α, IL-1, IL-6 and IL-8 in human blood cells. 2-Hydroxy Imiquimod exhibits antivirus and antitumor activities. 2-Hydroxy Imiquimod can be used for the researches of cancer, infection and immunology. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
O-Desethyl resiquimod-d6 | O-Desethyl resiquimod-d6 is the deuterium labeled O-Desethyl Resiquimod (HY-W749241). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
S-27609 | S-27609 is an imidazoquinoline with antiviral and antitumour properties. S-27609 can induce peripheral blood mononuclear cells to produce various cytokines such as interferon-α (IFN-α), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β). S-27609 is promising for research of viral infections (e.g., herpes virus) and tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
